Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Johnson and Johnson
Baxter
Harvard Business School

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for AZD-1981

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the development status for investigational drug AZD-1981?

AZD-1981 is an investigational drug.

There have been 30 clinical trials for AZD-1981. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Adenocarcinoma, Ovarian Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.

There are ten US patents protecting this investigational drug and one hundred and eighty-two international patents.

Recent Clinical Trials for AZD-1981
TitleSponsorPhase
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerNational Cancer Institute (NCI)Phase 2
Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerM.D. Anderson Cancer CenterPhase 2
Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerAstraZenecaPhase 2

See all AZD-1981 clinical trials

Clinical Trial Summary for AZD-1981

Top disease conditions for AZD-1981
Top clinical trial sponsors for AZD-1981

See all AZD-1981 clinical trials

US Patents for AZD-1981

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
AZD-1981   Start Trial Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors ASTRAZENECA AB (Sodertalje, SE)   Start Trial
AZD-1981   Start Trial Chemical compounds AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD-1981   Start Trial Substituted 3-sulfur indoles AstraZeneca AB (SE)   Start Trial
AZD-1981   Start Trial Process for the preparation of substituted indoles AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD-1981   Start Trial Pharmaceutical process and intermediates 714 AstraZeneca AB (Sodertalje, SE)   Start Trial
AZD-1981   Start Trial Substituted pyridinyl-pyrimidines and their use as medicaments Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for AZD-1981

Drugname Country Document Number Estimated Expiration Related US Patent
AZD-1981 Argentina 099177 2034-01-24   Start Trial
AZD-1981 Australia 2015208932 2034-01-24   Start Trial
AZD-1981 Australia 2017200338 2034-01-24   Start Trial
AZD-1981 Australia 2018202956 2034-01-24   Start Trial
AZD-1981 Australia 2019202675 2034-01-24   Start Trial
AZD-1981 Canada 2935625 2034-01-24   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
McKesson
Merck
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.